stockrow
Friday 6 November 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
Bolt Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, roughly unchanged from fiscal 2024.
- Revenue
- −99.7%
- EPS
- −2.47%
- Free cash flow
- +38.9%
- Total debt
- −14.3%
Quarter to June 2026, against a year earlier
6.52
0.14
+2.19%
Follow BOLT
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.39 | 1.04 | 1.33 | 1.97 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.00) | (0.85) | (1.43) | (1.05) | |
P/B ratio |
0.52 | 0.34 | 0.39 | 0.32 | |
Price to Tangible BV |
0.52 | 0.34 | 0.39 | 0.32 | |
EV/Sales |
1.54 | 0.47 | 0.35 | (0.31) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.04 | |
EV/Operating CF |
(0.23) | (0.09) | (0.07) | 0.03 | |
EV/FCF |
(0.24) | (0.09) | (0.07) | 0.03 | |
Quick Ratio |
2.26 | 3.14 | 3.28 | 3.28 | |
Current Ratio |
2.61 | 3.51 | 3.59 | 3.57 | |
Net Debt/EBITDA |
(0.09) | 0.50 | 1.08 | 1.57 | |
Debt/Assets |
45.94% | 40.29% | 35.48% | 32.11% | |
Debt/Equity |
1.47 | 0.98 | 0.76 | 0.65 | |
Asset Turnover |
0.08 | 0.10 | 0.10 | 0.06 | |
Operating CF/Net income |
0.85 | 1.11 | 1.08 | 1.36 | |
Capex/Depreciation |
7.16 | 0.20 | 0.00 | (0.45) | |
Research and Development Expense of Revenue |
102,980.00% | 18,573.08% | 199.52% | 301.29% | |
Selling, General and Administrative Expense of Revenue |
48,440.00% | 10,761.54% | 124.68% | 153.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11,040.00% | 2,096.15% | 41.64% | 18.76% | |
Graham Net Nets |
(1.10) | (0.36) | 0.00 | 0.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(427.01%) | (404.21%) | (325.78%) | (420.68%) | |
Free Cash Flow Yield |
(473.38%) | (509.03%) | (380.87%) | (452.86%) | |
Revenue per Share |
0.00 | 0.02 | 1.34 | 1.13 | |
Operating CF per Share |
(3.87) | (4.78) | (3.83) | (5.07) | |
Capex per Share |
0.40 | 0.02 | 0.00 | (0.04) | |
Free Cash Flow per Share |
(3.47) | (4.76) | (3.83) | (5.11) | |
Cash per Share |
10.53 | 13.75 | 14.82 | 17.04 | |
Shareholders Equity per Share |
7.47 | 11.80 | 14.17 | 16.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.47 | 11.80 | 14.17 | 16.73 | |
Free Cash Flow |
(5.87) | (7.99) | (7.16) | (9.80) | |
Working Capital |
12.70 | 18.41 | 21.83 | 25.64 | |
Capital Expenditures |
0.67 | 0.03 | 0.00 | (0.07) | |
Net Current Asset Value |
(7.14) | (2.45) | 0.02 | 2.65 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.03 | |
Capex to Sales |
(134.60) | (1.19) | 0.00 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.36 | 1.64 | 1.48 | 1.50 | |
Average Assets |
57.92 | 66.94 | 78.19 | 87.19 | |
Average Common Equity |
25.74 | 33.32 | 41.85 | 52.07 |
Columns are period end dates